PMID:40954312 Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers

[justaddcoffee]

@alzassistant summarize this paper: PMID:40954312 Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers

[alzassistant]

Summary of PMID:40954312

Title: Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers

Authors: Tideman P, Karlsson L, Strandberg O, et al.

Journal: Nature Medicine (2025)

DOI: 10.1038/s41591-025-03965-4

---

Key Findings

Novel Digital Cognitive Test (BioCog)

The researchers developed BioCog, a brief, self-administered digital cognitive test battery specifically designed for use in primary care settings. This addresses the urgent need to efficiently identify patients with cognitive impairment due to Alzheimer's disease (AD), particularly with the advent of amyloid-β-targeting therapies.

Study Design

• Development cohort: n=223 (secondary care)
• Validation cohort: n=403 across 19 primary care centers
• Logistic regression model based on BioCog sub-scores

Performance Results

BioCog Alone for Cognitive Impairment Detection:

• Single cutoff approach: 85% accuracy
• Two-cutoff approach: 90% accuracy
• Significantly outperformed:
  • Primary care physician assessments (73% accuracy)
  • Standard paper-and-pencil tests (MMSE, MoCA, Mini-Cog)
  • Other digital cognitive tests

BioCog + Blood Biomarkers for Clinical AD Detection:

• Combined approach: 90% accuracy (single cutoff)
• Significantly better than:
  • Standard-of-care alone (70% accuracy)
  • Blood test alone (80% accuracy)

Clinical Implications

1. Efficiency in Primary Care: BioCog provides a self-administered, time-efficient screening tool that doesn't require extensive clinical time

2. Superior Accuracy: Outperforms both physician assessment and traditional cognitive tests currently used in primary care

3. Biomarker Integration: When combined with blood biomarkers, achieves excellent accuracy (90%) for detecting biomarker-verified AD

4. Clinical Readiness: This proof-of-concept study demonstrates feasibility for implementation in real-world primary care settings with validation across 19 centers

Significance

This study is particularly timely given the recent approval of amyloid-targeting therapies (e.g., lecanemab, donanemab). The combination of a digital cognitive test with blood biomarkers could enable:

• Earlier and more accurate AD detection in primary care
• Efficient patient selection for specialty referral
• Better targeting of patients who may benefit from disease-modifying therapies
• Reduced burden on memory clinics by improving pre-screening accuracy

Limitations

• The paper is currently ahead of print (published September 2025)
• Full text not available through Europe PMC at this time
• Based on metadata, this appears to be a proof-of-concept study requiring further validation

---

Note: This summary is based on the abstract and metadata from PubMed/Europe PMC. Full text access would provide additional details about methodology, specific biomarkers used, patient characteristics, and detailed performance metrics across different subgroups.